NYSE:IQV - Iqvia Stock Price, News & Analysis

$154.15
+0.71 (+0.46 %)
(As of 09/19/2019 01:09 PM ET)
Today's Range
$153.14
Now: $154.15
$155.26
50-Day Range
$149.93
MA: $154.56
$160.74
52-Week Range
$104.90
Now: $154.15
$164.13
Volume34,328 shs
Average Volume1.11 million shs
Market Capitalization$30.20 billion
P/E Ratio30.17
Dividend YieldN/A
Beta0.9
IQVIA Holdings Inc provides advanced analytics, technology solutions, and contract research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation, real-world insights, and reference information services; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. Read More…

Industry, Sector and Symbol

Industry Commercial physical research
Sub-IndustryN/A
SectorBusiness Services
CUSIPN/A
Phone919-998-2000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$10.41 billion
Cash Flow$11.3346 per share
Book Value$34.76 per share

Profitability

Net Income$259 million

Miscellaneous

Employees58,000
Market Cap$30.20 billion
Next Earnings Date10/28/2019 (Estimated)
OptionableOptionable

Receive IQV News and Ratings via Email

Sign-up to receive the latest news and ratings for IQV and its competitors with MarketBeat's FREE daily newsletter.


Iqvia (NYSE:IQV) Frequently Asked Questions

What is Iqvia's stock symbol?

Iqvia trades on the New York Stock Exchange (NYSE) under the ticker symbol "IQV."

How were Iqvia's earnings last quarter?

Iqvia Holdings Inc (NYSE:IQV) posted its quarterly earnings results on Wednesday, July, 24th. The medical research company reported $1.39 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.38 by $0.01. The medical research company earned $2.74 billion during the quarter, compared to the consensus estimate of $2.70 billion. Iqvia had a net margin of 2.31% and a return on equity of 15.95%. Iqvia's revenue was up 6.7% compared to the same quarter last year. During the same quarter last year, the firm posted $1.29 EPS. View Iqvia's Earnings History.

When is Iqvia's next earnings date?

Iqvia is scheduled to release their next quarterly earnings announcement on Monday, October 28th 2019. View Earnings Estimates for Iqvia.

What guidance has Iqvia issued on next quarter's earnings?

Iqvia issued an update on its FY19 earnings guidance on Wednesday, July, 24th. The company provided earnings per share guidance of $6.25-6.45 for the period, compared to the Thomson Reuters consensus estimate of $6.33. The company issued revenue guidance of $11.00-1.15 billion, compared to the consensus revenue estimate of $11.02 billion.

What price target have analysts set for IQV?

19 Wall Street analysts have issued 1-year target prices for Iqvia's shares. Their predictions range from $136.38 to $180.00. On average, they expect Iqvia's stock price to reach $163.3363 in the next year. This suggests a possible upside of 6.0% from the stock's current price. View Analyst Price Targets for Iqvia.

What is the consensus analysts' recommendation for Iqvia?

19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Iqvia in the last year. There are currently 2 hold ratings, 16 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Iqvia.

Has Iqvia been receiving favorable news coverage?

Media coverage about IQV stock has been trending negative recently, according to InfoTrie Sentiment. InfoTrie identifies negative and positive media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Iqvia earned a daily sentiment score of -2.9 on InfoTrie's scale. They also gave news coverage about the medical research company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the immediate future. View News Stories for Iqvia.

Are investors shorting Iqvia?

Iqvia saw a decrease in short interest in August. As of August 31st, there was short interest totalling 2,240,600 shares, a decrease of 9.5% from the July 31st total of 2,474,900 shares. Based on an average daily volume of 1,230,000 shares, the days-to-cover ratio is currently 1.8 days. Currently, 1.3% of the shares of the stock are sold short. View Iqvia's Current Options Chain.

Who are some of Iqvia's key competitors?

What other stocks do shareholders of Iqvia own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Iqvia investors own include CA (CA), BlackRock (BLK), Endologix (ELGX), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), Allergan (AGN), Micron Technology (MU), NIC (EGOV), Zoetis (ZTS) and Workday (WDAY).

Who are Iqvia's key executives?

Iqvia's management team includes the folowing people:
  • Mr. Ari Bousbib, Chairman, Pres & CEO (Age 58)
  • Mr. Michael R. McDonnell, Exec. VP & CFO (Age 55)
  • Mr. Eric M. Sherbet, Exec. VP, Gen. Counsel & Sec. (Age 55)
  • Mr. W. Richard Staub III, Pres of R&D Solutions (Age 56)
  • Mr. Kevin C. Knightly, Pres of Information & Technology Solutions (Age 58)

Who are Iqvia's major shareholders?

Iqvia's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (9.35%), BlackRock Inc. (6.86%), BlackRock Inc. (6.86%), Janus Henderson Group PLC (1.85%), Janus Henderson Group PLC (1.85%) and AQR Capital Management LLC (1.43%). Company insiders that own Iqvia stock include Ari Bousbib, Canada Pension Plan Investment, Cpp Investment Board Private H, Group Holdings (Sbs) Advis Tpg, Jack M Greenberg, James H Erlinger III, John Connaughton, John G Danhakl, Kevin C Knightly, Michael J Evanisko, Michael R Mcdonnell, Robert Parks, Ronald A Rittenmeyer and W Richard Staub. View Institutional Ownership Trends for Iqvia.

Which institutional investors are selling Iqvia stock?

IQV stock was sold by a variety of institutional investors in the last quarter, including Price T Rowe Associates Inc. MD, Morgan Stanley, AQR Capital Management LLC, Eminence Capital LP, Bank of New York Mellon Corp, Quest Capital Management Inc. ADV, AMF Pensionsforsakring AB and Highline Capital Management L.P.. Company insiders that have sold Iqvia company stock in the last year include Ari Bousbib, Canada Pension Plan Investment, Group Holdings (Sbs) Advis Tpg, Kevin C Knightly, Michael J Evanisko, Michael R Mcdonnell, Ronald A Rittenmeyer and W Richard Staub. View Insider Buying and Selling for Iqvia.

Which institutional investors are buying Iqvia stock?

IQV stock was purchased by a variety of institutional investors in the last quarter, including Investec Asset Management LTD, Nuveen Asset Management LLC, Egerton Capital UK LLP, BlackRock Inc., BlackRock Inc., Putnam Investments LLC, Janus Henderson Group PLC and Janus Henderson Group PLC. View Insider Buying and Selling for Iqvia.

How do I buy shares of Iqvia?

Shares of IQV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Iqvia's stock price today?

One share of IQV stock can currently be purchased for approximately $154.15.

How big of a company is Iqvia?

Iqvia has a market capitalization of $30.20 billion and generates $10.41 billion in revenue each year. The medical research company earns $259 million in net income (profit) each year or $5.12 on an earnings per share basis. Iqvia employs 58,000 workers across the globe.View Additional Information About Iqvia.

What is Iqvia's official website?

The official website for Iqvia is http://www.iqvia.com/.

How can I contact Iqvia?

Iqvia's mailing address is 4820 EMPEROR BLVD, DURHAM NC, 27703. The medical research company can be reached via phone at 919-998-2000 or via email at [email protected]


MarketBeat Community Rating for Iqvia (NYSE IQV)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  456 (Vote Outperform)
Underperform Votes:  402 (Vote Underperform)
Total Votes:  858
MarketBeat's community ratings are surveys of what our community members think about Iqvia and other stocks. Vote "Outperform" if you believe IQV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IQV will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/19/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel